Profile data is unavailable for this security.
About the company
Catalyst Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on developing and commercializing first-in-class medicines that address rare and difficult to treat diseases. Its flagship commercial product is FIRDAPSE (amifampridine) tablets 10 milligrams (mg), approved for the treatment of Lambert-Eaton Myasthenic Syndrome (LEMS) for adults and for children ages six to seventeen. The Company is also marketing FYCOMPA (perampanel) CIII as a prescription medication used alone or with other medicines to treat focal onset seizures with or without secondarily generalized seizures in people with epilepsy aged four and older and with other medicines to treat primary generalized tonic-clonic seizures in people with epilepsy aged 12 and older. Its portfolio also includes AGAMREE (vamorolone) an oral suspension 40 mg/ml for the treatment of Duchenne Muscular Dystrophy (DMD). The vamorolone is a corticosteroid treatment for patients suffering from DMD.
- Revenue in USD (TTM)434.48m
- Net income in USD68.15m
- Incorporated2006
- Employees167.00
- LocationCatalyst Pharmaceuticals Inc355 ALHAMBRA CIRCLE, SUITE 801CORAL GABLES 33134United StatesUSA
- Phone+1 (305) 529-2522
- Fax+1 (302) 636-5454
- Websitehttps://catalystpharma.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Tilray Brands Inc | 788.94m | -244.98m | 1.47bn | 2.65k | -- | 0.4156 | -- | 1.87 | -0.3334 | -0.3334 | 1.06 | 4.14 | 0.185 | 2.50 | 8.40 | 297,714.00 | -5.22 | -- | -5.72 | -- | 28.31 | -- | -28.19 | -- | 1.42 | -0.9071 | 0.0963 | -- | 25.80 | -- | 83.14 | -- | -- | -- |
Harrow Inc | 154.15m | -33.58m | 1.60bn | 315.00 | -- | 27.29 | -- | 10.36 | -0.9508 | -0.9508 | 4.38 | 1.65 | 0.581 | 4.95 | 4.39 | 489,352.40 | -12.66 | -10.86 | -14.77 | -12.71 | 71.16 | 70.75 | -21.78 | -15.35 | 2.43 | -0.3518 | 0.7608 | -- | 46.95 | 25.77 | -73.30 | -- | 143.88 | -- |
Immunocore Holdings PLC - ADR | 281.45m | -53.44m | 1.66bn | 497.00 | -- | -- | -- | 5.90 | -1.07 | -1.07 | 5.55 | -- | 0.3556 | 0.5679 | 5.56 | 566,303.60 | -6.75 | -27.55 | -8.35 | -36.82 | 99.41 | -- | -18.99 | -97.12 | 5.15 | -- | 0.5495 | -- | 43.05 | 51.23 | -5.22 | -- | 2.85 | -- |
Supernus Pharmaceuticals Inc | 630.16m | 5.24m | 1.75bn | 652.00 | 360.24 | 1.83 | 19.43 | 2.78 | 0.0883 | 0.0883 | 11.39 | 17.39 | 0.4831 | 0.9256 | 4.36 | 966,507.70 | 0.4016 | 4.95 | 0.5117 | 6.41 | 88.34 | 88.61 | 0.8314 | 12.84 | 1.69 | -- | 0.00 | -- | -8.95 | 8.24 | -97.83 | -58.81 | -8.17 | -- |
Ligand Pharmaceuticals Inc | 133.48m | 42.14m | 1.88bn | 58.00 | 46.20 | 2.40 | 24.30 | 14.07 | 2.22 | 2.22 | 7.33 | 42.82 | 0.1643 | 0.4789 | 4.08 | 2,301,345.00 | 5.19 | 12.32 | 5.35 | 12.99 | 91.82 | 81.65 | 31.57 | 80.32 | 15.81 | -- | 0.00002 | -- | -33.09 | -12.18 | 1,131.21 | -17.86 | 42.63 | -- |
Endo Inc | -100.00bn | -100.00bn | 2.02bn | 3.00k | -- | 1.10 | -- | -- | -- | -- | -- | 23.99 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 1.52 | -- | 0.5697 | -- | -13.25 | -- | 15.87 | -- | -- | -- |
Harmony Biosciences Holdings Inc | 656.11m | 114.99m | 2.23bn | 246.00 | 20.12 | 4.15 | 16.02 | 3.40 | 1.95 | 1.95 | 11.19 | 9.48 | 0.8107 | 25.74 | 8.93 | 2,667,110.00 | 14.21 | 7.46 | 16.68 | 9.08 | 79.41 | 80.58 | 17.53 | 10.46 | 3.09 | 52.20 | 0.2571 | 0.00 | 32.93 | -- | -28.99 | -- | -25.31 | -- |
Vericel Corp | 214.52m | 789.00k | 2.28bn | 314.00 | 2,462.72 | 9.37 | 384.53 | 10.64 | 0.0189 | 0.0189 | 4.46 | 4.97 | 0.624 | 4.41 | 4.97 | 683,184.70 | 0.2295 | -3.07 | 0.2595 | -3.50 | 70.42 | 67.87 | 0.3678 | -4.49 | 4.16 | -- | 0.0008 | -- | 20.17 | 16.80 | 80.96 | -- | 59.35 | -- |
Amphastar Pharmaceuticals Inc | 712.89m | 166.52m | 2.39bn | 1.76k | 15.67 | 3.38 | 10.90 | 3.36 | 3.14 | 3.14 | 13.45 | 14.57 | 0.4968 | 2.85 | 6.04 | 404,821.70 | 11.71 | 9.42 | 13.54 | 11.56 | 54.68 | 47.83 | 23.56 | 15.23 | 2.63 | 7.42 | 0.4515 | 0.00 | 29.14 | 16.94 | 50.51 | -- | -4.00 | -- |
Catalyst Pharmaceuticals Inc | 434.48m | 68.15m | 2.47bn | 167.00 | 38.97 | 4.05 | 23.56 | 5.68 | 0.5335 | 0.5335 | 3.71 | 5.14 | 0.7554 | 4.03 | 8.69 | 2,601,647.00 | 11.85 | 25.42 | 13.56 | 29.81 | 86.67 | 85.63 | 15.69 | 30.87 | 4.94 | -- | 0.00 | 0.00 | 85.90 | 280.39 | -14.05 | -- | 20.21 | -- |
Amneal Pharmaceuticals Inc | 2.60bn | -174.62m | 2.69bn | 7.70k | -- | -- | 29.26 | 1.04 | -0.6224 | -0.6224 | 10.09 | -0.1857 | 0.7206 | 3.00 | 3.60 | 337,401.60 | -3.69 | -4.80 | -4.93 | -5.93 | 35.04 | 34.76 | -5.13 | -9.00 | 0.8165 | 1.24 | 1.00 | -- | 8.20 | 7.56 | 35.38 | -- | -6.55 | -- |
Twist Bioscience Corp | 295.21m | -220.31m | 2.72bn | 919.00 | -- | 5.53 | -- | 9.22 | -3.81 | -3.81 | 5.12 | 8.39 | 0.4076 | 5.42 | 8.56 | 321,229.60 | -30.42 | -30.50 | -33.85 | -33.84 | 40.53 | 36.02 | -74.63 | -113.33 | 4.52 | -- | 0.00 | -- | 20.41 | 57.33 | 6.08 | -- | 49.76 | -- |
Holder | Shares | % Held |
---|---|---|
BlackRock Fund Advisorsas of 30 Jun 2024 | 16.52m | 13.92% |
The Vanguard Group, Inc.as of 30 Jun 2024 | 7.79m | 6.56% |
SSgA Funds Management, Inc.as of 30 Jun 2024 | 6.03m | 5.08% |
Pacer Advisors, Inc.as of 30 Jun 2024 | 2.97m | 2.50% |
Dimensional Fund Advisors LPas of 30 Jun 2024 | 2.85m | 2.40% |
Geode Capital Management LLCas of 30 Jun 2024 | 2.70m | 2.27% |
First Trust Advisors LPas of 30 Jun 2024 | 2.47m | 2.08% |
Renaissance Technologies LLCas of 30 Jun 2024 | 2.18m | 1.83% |
Royce & Associates LPas of 30 Jun 2024 | 2.16m | 1.82% |
Janus Henderson Investors US LLCas of 30 Jun 2024 | 2.13m | 1.79% |